MarketBeat
06 Jun 2026, 12:05 UTC · 15w ago
Verdict
Headline takes no side. We score BIOA +0.60 across five claims — strongly bullish.
+0.60strongly bullish
More positive than 73% of ticker scores this week
What the story claims
5 claims · scored −1 bearish … +1 bullish
BioAge expects Phase 2 cardiovascular risk dose-ranging results for its lead candidate BGE-102 by the end of the year.
More positive than 92% of claims this week
BGE-102 demonstrated an 86% reduction in high-sensitivity CRP in Phase 1, with 87-93% of patients reaching the <2 mg/L threshold associated with higher cardiovascular benefit.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
More positive than 85% of claims this week
BioAge will initiate a proof-of-concept trial for diabetic macular edema (DME) in mid-2024, with data expected in mid-2025.
More positive than 63% of claims this week
The company reported approximately $385 million in cash at the end of Q1, which it claims provides substantial funding toward a potential MACE study.
So whatStrong liquidity reduces immediate dilution risk and suggests the company can execute its near-term clinical roadmap.
More positive than 50% of claims this week
BioAge plans to file its first IND for its APJ agonist programs by the end of the year.
More positive than 50% of claims this week
Which stocks this story touches
More positive than 73% of ticker scores this week
Company reported strong Phase 1 biomarker reductions for BGE-102 and has significant cash reserves to fund upcoming trials.
More positive than 51% of ticker scores this week
The success of their ziltivekimab trial would validate the inflammatory axis approach, which is a positive catalyst for the program.
More positive than 45% of ticker scores this week
Mentioned positively in the context of acquiring Ventyx to gain access to NLRP3 inhibition technology.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Seeking Alpha
4h ago
Accesswire
7h ago
−50.4%
Price is moving against the score
$7.79 vs $15.70 close before publication (Jun 5) · not market-adjusted
BIOA chart →
